Paper Details

  1. Home
  2. Paper Details

Tolerability of first-line therapy for metastatic renal cell carcinoma.

Author: PortaCamillo, SzczylikCezary

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

The treatment options for metastatic renal cell carcinoma (RCC) have expanded significantly in recent years, with four new agents available and others in development. This has changed the standard of first-line care, with sunitinib or bevacizumab plus interferon favored for patients with good or intermediate-risk RCC, and temsirolimus for poor-risk disease. While sunitinib and bevacizumab plus interferon have similar efficacy, treatment choice is further influenced by factors such as tumor histology, patient comorbidities, Memorial Sloan-Kettering Cancer Center risk assessment, and patient preference. This review focuses on the tolerability of first-line treatment options for clear cell RCC, considering how tolerability profiles relate to drug mechanisms of action. It describes the incidence and causes of side effects associated with vascular endothelial growth factor (VEGF) and VEGF receptor inhibition using sunitinib and bevacizumab, as well as the non-specific side effects of sunitinib. The review also considers the potential patient impact and management of these side effects, as well as those of interferon and temsirolimus. Finally, it assesses the implications of tolerability profiles for combination therapy and broader patient populations beyond those enrolled in trials.
Paper Details　
Original Abstract of the Article :
The treatment options for metastatic renal cell carcinoma have expanded rapidly over the past 3 years, with four new agents available and others in late-stage development. This has resulted in a change of the standard of first-line care, with sunitinib or bevacizumab plus interferon the treatments o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ctrv.2008.12.003

データ提供：米国国立医学図書館（NLM）

Navigating the Tolerability Landscape of First-Line Therapies for Metastatic Renal Cell Carcinoma

The treatment landscape for metastatic renal cell carcinoma has significantly evolved in recent years, offering patients a wider range of therapies. This review examines the tolerability profiles of first-line treatment options for clear cell renal cell carcinoma, considering the impact of side effects on patient well-being. The authors focus on the tolerability of sunitinib, bevacizumab plus interferon, and temsirolimus, highlighting the importance of choosing the most suitable treatment based on individual patient factors and disease characteristics.

Tolerability of First-Line Therapies: A Balancing Act of Benefits and Risks

The review highlights the varying tolerability profiles of different therapies. Sunitinib and bevacizumab plus interferon are associated with side effects related to vascular endothelial growth factor and vascular endothelial growth factor receptor inhibition, while temsirolimus has a different set of potential side effects. Clinicians must carefully consider these factors when choosing the optimal treatment for each patient.

Making Informed Decisions: Understanding the Tolerability Profiles of Cancer Therapies

This review underscores the importance of understanding the potential side effects of cancer treatments. It's like navigating a desert with multiple paths, each with its own set of obstacles. Patients and their clinicians must weigh the potential benefits of a treatment against its risks and side effects to make informed decisions about their care. This review provides valuable information to guide these crucial decisions.

Dr.Camel's Conclusion

This research illuminates the complex landscape of cancer treatment options. It's like a desert oasis, where each treatment offers potential benefits but also presents challenges. The review emphasizes the need for personalized care, considering both the potential benefits and risks of each treatment option. By understanding the tolerability profiles of various therapies, clinicians can make informed decisions to optimize patient care and improve their quality of life.

Date :
  1. Date Completed 2009-04-21
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

19249157

DOI: Digital Object Identifier

10.1016/j.ctrv.2008.12.003

Related Literature

Article Analysis
・Side Effects of temsirolimus
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.